Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hassel

Showing results (251-260 of 271) with videos related to

Pageof 28
Sort By:
Cancer Discovery|November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanomaEliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
Nature Cancer|June 17, 2022
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapyThomas Walle, Sunanjay Bajaj, Joscha A Kraske, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Cancers|July 20, 2021
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic MetastasisElias A T Koch, Anne Petzold, Anja Wessely, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2026
Translating ctDNA into cutaneous melanoma care: An international expert surveyGlenn Geidel, Nathan Fekade, Katharina Raabe, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Frontiers in Oncology|November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter AnalysisAnne Zaremba, Rafaela Kramer, Viola De Temple, et al.
Pageof 28

Showing results (251-260 of 271) with videos related to

Sort By:
Pageof 28
Cancer Discovery|November 23, 2013
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanomaEliezer M Van Allen, Nikhil Wagle, Antje Sucker, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
Nature Cancer|June 17, 2022
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapyThomas Walle, Sunanjay Bajaj, Joscha A Kraske, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2025
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanomaK C Kähler, J C Hassel, M Ziemer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Cancers|July 20, 2021
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic MetastasisElias A T Koch, Anne Petzold, Anja Wessely, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2026
Translating ctDNA into cutaneous melanoma care: An international expert surveyGlenn Geidel, Nathan Fekade, Katharina Raabe, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Frontiers in Oncology|November 8, 2021
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter AnalysisAnne Zaremba, Rafaela Kramer, Viola De Temple, et al.
Pageof 28